Patients requiring further treatment upon tumor progression with 2L treatment received a median of 1.5 subsequent treatment lines (range: 1–3), which comprised either a rechallenge with BRAF ± MEKi (n = 47), CPI-rechallenge (n = 50) or other treatments (i.e., study medications or chemotherapy; n = 3). The gene discussed is BRAF; the disease is neoplasm.